MannKind to buy scPharmaceuticals for $5.35 per share in cash
ByAinvest
Monday, Aug 25, 2025 7:30 am ET1min read
MannKind to buy scPharmaceuticals for $5.35 per share in cash
MannKind Corporation (NASDAQ: MNKD) has announced its intention to acquire scPharmaceuticals, Inc. in a cash deal valued at $5.35 per share. The acquisition, which is expected to close in the third quarter of 2025, aims to expand MannKind's portfolio of inhaled therapeutic products and strengthen its position in the rare lung diseases market [1].The deal comes on the heels of MannKind's solid performance during the fiscal second quarter of 2025, as reported by Faisal Khurshid from Leerink Partners, who reiterated a Buy rating on the company with a price target of $7 [1]. The analyst highlighted MannKind's progress in treating idiopathic pulmonary fibrosis, nontuberculous mycobacterial lung disease, and pediatric uses of Afrezza.
The acquisition of scPharmaceuticals will enhance MannKind's capabilities in developing and commercializing inhaled therapeutic products for endocrine and rare lung diseases. This move is expected to bolster MannKind's revenue streams and solidify its market position.
The transaction will be funded through a combination of cash and debt financing. The total consideration for the acquisition is approximately $1.1 billion, which is expected to be funded through a combination of cash on hand and new debt financing.
MannKind's stock has been volatile in recent years, but the company's strong pipeline and recent quarterly results have drawn positive attention from analysts. While the acquisition of scPharmaceuticals may introduce additional risks, it also presents significant opportunities for growth.
MannKind's management has expressed optimism about the deal, noting that it aligns with the company's strategic goals and will enable it to better serve its patients and investors. The acquisition is subject to regulatory approval and other customary closing conditions.
References:
[1] https://finance.yahoo.com/news/leerink-partners-reiterates-buy-mannkind-034530254.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet